Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$11.52 USD
+0.31 (2.77%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Theravance Biopharma, Inc. has a market cap of $560.52M, which represents its share price of $11.21 multiplied by its outstanding shares number of 50.00M. As a small-cap company, TBPH's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TBPH 11.52 +0.31(2.77%)
Will TBPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Other News for TBPH
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 | TBPH ...
Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News
Theravance Biopharma (TBPH) Target Price Raised to $25 By BTIG | TBPH Stock News
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News
Theravance Biopharma price target raised to $25 from $24 at BTIG